# Atypical Parkinsonism

Evaluate progressive parkinsonism for early autonomic failure, vertical gaze dysfunction, falls, cortical deficits, cognitive fluctuation, or poor levodopa response to distinguish multiple system atrophy, progressive supranuclear palsy, corticobasal syndrome, and dementia with Lewy bodies from Parkinson disease.

**Clinical question:** How should clinicians distinguish and manage the major atypical parkinsonian syndromes in patients with progressive parkinsonism?

Updated: 2026-08-21T02:03:22.701267+00:00

## What matters in practice
- Treat “Parkinson-plus syndrome” as a clinical prompt to identify a specific syndrome—MSA, PSP, corticobasal syndrome, or DLB—rather than as a final diagnosis.[2][4][5]
- Early, severe dysautonomia with parkinsonism and/or cerebellar ataxia should redirect the evaluation toward MSA and away from idiopathic Parkinson disease.[2][9]
- Early postural instability and falls, axial-predominant parkinsonism, and supranuclear vertical gaze impairment strongly favor PSP phenotypes.[6]
- Asymmetric cortical motor and cognitive findings—especially apraxia, cortical sensory deficits, alien-limb phenomena, or progressive aphasia—support corticobasal syndrome, but corticobasal degeneration remains a pathologic diagnosis.[4][6][7]
- Management is predominantly symptomatic and requires repeated examination for evolving gait, bulbar, autonomic, cognitive, behavioral, and caregiver-safety needs.[2][7][8]

## Identify red flags that warrant an atypical parkinsonism pathway

Use the tempo and nonmotor syndrome to determine whether routine Parkinson disease management is likely to be insufficient.

In a patient with progressive parkinsonism, initiate an atypical-parkinsonism evaluation when motor impairment is levodopa-poorly responsive or when early gait instability, falls, dysautonomia, cerebellar signs, prominent cognitive-behavioral change, eye-movement abnormalities, or cortical deficits accompany parkinsonism.[2][3][5] The principal syndromic branches are multiple system atrophy (MSA), progressive supranuclear palsy (PSP), corticobasal syndrome (CBS), and dementia with Lewy bodies (DLB).[2][4][5]

Do not equate a clinical syndrome with a neuropathologic diagnosis. PSP and corticobasal degeneration are primary tauopathies, but the classic clinical corticobasal syndrome does not reliably establish corticobasal degeneration during life; use “CBS” for the clinical phenotype and reserve “CBD” for pathologically confirmed disease when possible.[4][6][7] Likewise, clinical classification in specialized centers is useful but remains imperfect relative to neuropathology.[2]

Escalate urgently when falls, dysphagia, aspiration risk, severe orthostatic symptoms, urinary retention, delirium, or caregiver inability to maintain safety becomes apparent. These complications change near-term management even when syndromic classification remains provisional; reassess medications for benefit and toxicity at each visit.[7]
- Document the chronology of autonomic symptoms, cognitive change, falls, eye-movement symptoms, speech/language decline, limb asymmetry, cerebellar symptoms, and motor response to levodopa; nonmotor symptoms may precede or occur independently of motor severity.[3]
- Perform a focused neurologic examination at every reassessment: eye movements, axial versus limb rigidity, spontaneous retropulsion or pull-test instability, cerebellar signs, pyramidal signs, praxis, cortical sensory testing, language, cognition, and autonomic symptom review.[2][5][7]
- Refer to a movement-disorders center when the phenotype is mixed, rapidly evolving, potentially genetic, or inconsistent with a degenerative syndrome; nondegenerative and genetic disorders can mimic atypical parkinsonism and may alter counseling or treatment.[4][9]

*Syndromic bedside patterns that direct the next diagnostic branch.[2][4][5][6][9]*

| Predominant clinical pattern | Leading syndrome | Next diagnostic emphasis |
| --- | --- | --- |
| Parkinsonism with prominent dysautonomia; may include cerebellar ataxia or corticospinal findings | Multiple system atrophy | Characterize autonomic failure and search for MSA mimics, including treatable nondegenerative disorders.[9] |
| Axial-predominant parkinsonism, early falls, vertical supranuclear gaze dysfunction, pseudobulbar features | Progressive supranuclear palsy | Define PSP phenotype with serial oculomotor, gait, bulbar, and cognitive examinations.[6][7] |
| Markedly asymmetric parkinsonism with apraxia, cortical sensory deficits, alien-limb phenomena, or progressive aphasia | Corticobasal syndrome | Document cortical deficits and counsel that the underlying pathology cannot be established reliably from syndrome alone.[4][6][7] |
| Parkinsonism with dementia syndrome and neuropsychiatric/cognitive features | Dementia with Lewy bodies | Assess cognition, behavior, hallucinations, sleep-related symptoms, medication sensitivity, and caregiver burden longitudinally.[2][3] |

## Use serial phenotyping and targeted testing rather than a single confirmatory test

The clinical examination remains the diagnostic anchor; testing is used to support phenotyping and exclude important mimics.

Obtain brain MRI when atypical features are present, because structural imaging contributes to syndrome-based classification and helps evaluate alternative structural explanations for progressive parkinsonism.[2][5] Interpret MRI alongside the evolving neurologic phenotype rather than as a stand-alone diagnosis, since clinical and imaging-based classification is not perfectly concordant with neuropathology.[2]

In suspected MSA, separate neurogenic autonomic failure from common competing causes of orthostatic symptoms and evaluate the broader phenotype for parkinsonism, cerebellar ataxia, and corticospinal involvement.[9] A diagnostic error matters because MSA has a broad differential that includes nondegenerative disorders, some of which require different or potentially treatable interventions.[9]

Use targeted genetic evaluation when age at onset, family history, phenotype, or imaging suggests an inherited mimic. Genetic conditions can present with PSP-, CBS-, or MSA-like syndromes, and hereditary diffuse leukoencephalopathy with spheroids associated with CSF1R mutations is one reported example of a parkinsonian mimic.[4]

Alpha-synuclein seeding amplification assays in CSF, skin, and potentially blood are emerging biologic tools for synucleinopathies, but they require careful validation before they can replace expert clinical assessment or determine an individual patient’s diagnosis.[1] Do not delay safety-directed interventions while awaiting biomarker development or research-based testing.
- If the presentation is predominantly autonomic, prioritize MSA versus autonomic and nondegenerative mimics before assigning a Parkinson-plus label.[9]
- If the presentation is gaze-palsy and fall predominant, document supranuclear ocular motor dysfunction and distinguish PSP phenotypes from other neurodegenerative and genetic disorders with similar clinical appearances.[4][6]
- If the presentation is asymmetric cortical-motor or language predominant, document apraxia, cortical sensory function, alien-limb phenomena, and aphasia; classify clinically as CBS rather than presuming CBD pathology.[4][6][7]
- Reclassify at follow-up when new autonomic, oculomotor, cerebellar, cortical, cognitive, or bulbar signs emerge; early differentiation from Parkinson disease and among atypical syndromes is often difficult.[1][2]

*Testing and interpretation in suspected atypical parkinsonism.[1][2][4][5][9]*

| Test or assessment | When to use it | Interpretation and action |
| --- | --- | --- |
| Serial movement-disorders examination | All suspected cases | Track emergence of autonomic, ocular motor, cerebellar, cortical, cognitive, and bulbar features that refine syndromic classification.[1][2][5] |
| Brain MRI | Atypical clinical features or concern for structural/alternative causes | Use imaging as one component of syndrome-based evaluation and mimic exclusion; do not treat imaging alone as pathologic confirmation.[2][5] |
| Autonomic-focused assessment | Parkinsonism with orthostatic, urinary, or other autonomic symptoms | A prominent autonomic syndrome with parkinsonism and/or ataxia supports the MSA branch and requires evaluation for mimics.[9] |
| Targeted genetic evaluation | Family history, early onset, atypical phenotype, or imaging suggesting inherited disease | Consider genetic mimics of PSP-, CBS-, and MSA-like presentations; a result may redirect diagnosis and counseling.[4] |
| Alpha-synuclein seeding amplification assay | Selected specialist or research-context cases | Potentially supports a synucleinopathy but remains an evolving biomarker requiring further validation.[1] |

## Treat the dominant disability while continuing diagnostic surveillance

No disease-modifying treatment is established; management is symptom-directed and multidisciplinary.

Current treatment for atypical parkinsonian syndromes is symptomatic.[2][8] A levodopa trial may be clinically reasonable when parkinsonism is disabling, but poor levodopa responsiveness is common across atypical parkinsonism and should prompt a shift toward function-directed interventions rather than repeated escalation of ineffective dopaminergic therapy.[2][3][6] At every visit, reconcile medications and discontinue or reduce agents with no meaningful benefit or unacceptable toxicity.[7]

For PSP and CBS, prioritize falls prevention, transfer safety, gait and balance interventions, dysarthria and dysphagia assessment, and caregiver planning early because axial impairment, postural instability, bulbar dysfunction, and progressive functional dependency commonly drive morbidity.[6][7] Reassess swallowing and communication as symptoms evolve; the management consensus emphasizes regular identification of problems requiring treatment rather than waiting for a fixed diagnostic label.[2][7]

For MSA, address the autonomic syndrome in parallel with motor disability. Its characteristic combination of autonomic failure with variably expressed parkinsonism, cerebellar ataxia, and corticospinal features requires repeated review of orthostatic symptoms, urinary dysfunction, gait safety, and treatment adverse effects.[9] Diagnostic delays and misdiagnosis are common, so reconsider competing causes when the clinical pattern is discordant or treatment response is unexpected.[9]

For DLB-spectrum presentations, assess cognitive impairment, behavioral and neuropsychiatric symptoms, caregiver strain, and medication effects as core management targets rather than considering them secondary to motor severity.[2][3] Cognitive and neuropsychiatric manifestations may occur early and can substantially affect patient and caregiver quality of life.[3]
- Use physical therapy and occupational therapy when falls, freezing, impaired transfers, limb apraxia, or loss of activities of daily living is present; reassess assistive-device needs as function changes.[7]
- Obtain speech-language pathology assessment for dysarthria, apraxia of speech, progressive aphasia, coughing with meals, weight loss, or other suspected dysphagia; PSP and CBS commonly require bulbar and communication-focused management.[6][7]
- Coordinate movement-disorders neurology, rehabilitation, speech-language pathology, autonomic-focused care when relevant, and palliative-care discussions as progressive disability or complex symptom burden emerges.[7]
- Provide anticipatory counseling that syndrome-level diagnosis may evolve and that CBD is generally a neuropathologic designation rather than a diagnosis established with certainty in life.[4][7]

### When to intensify safety planning

Increase visit frequency and involve caregivers directly after recurrent falls, aspiration concern, rapidly worsening mobility, severe autonomic symptoms, or emerging cognitive-behavioral impairment. These events are actionable regardless of whether the phenotype is ultimately classified as PSP, MSA, CBS, or DLB.[2][3][7][9]
- Review the home environment, supervision needs, transfer technique, medication burden, and advance-care preferences when falls or functional decline accelerate.[7]
- Reassess whether continued diagnostic testing will change treatment, counseling, research eligibility, or identification of a treatable mimic.[1][4][9]

*Phenotype-directed management priorities in atypical parkinsonism.[2][3][6][7][9]*

| Clinical branch | Dominant management targets | Monitoring focus |
| --- | --- | --- |
| MSA | Autonomic symptoms, parkinsonism, ataxia, gait safety, and treatment adverse effects.[9] | Orthostatic and urinary symptoms; falls; cerebellar and corticospinal progression; diagnostic discordance suggesting a mimic.[9] |
| PSP | Falls prevention, axial mobility, bulbar dysfunction, communication, and cognitive-behavioral complications.[6][7] | Postural instability, ocular motor impairment, dysphagia, speech decline, and caregiver support needs.[6][7] |
| CBS | Apraxia, asymmetric limb dysfunction, speech/language impairment, mobility, and caregiver adaptation.[6][7] | Progression of cortical deficits, functional dependence, dysphagia, and evolving phenotype that may clarify underlying disease.[4][6][7] |
| DLB | Cognition, neuropsychiatric symptoms, parkinsonism, medication effects, and caregiver burden.[2][3] | Cognitive and behavioral change, motor function, safety, and functional impact on the caregiver-patient dyad.[3] |

## Communicate diagnostic uncertainty precisely and refer for evolving or mixed phenotypes

A provisional syndrome diagnosis can guide care without overstating pathologic certainty.

Document both the motor syndrome and the dominant nonmotor phenotype: for example, “progressive parkinsonism with severe autonomic failure, clinically most consistent with MSA” or “asymmetric cortical parkinsonism consistent with CBS.” This separates a useful clinical working diagnosis from a pathologic claim that may not be knowable during life.[4][6][7]

Refer for subspecialty reassessment when there is rapid progression, mixed syndromic features, a young or familial presentation, abnormal imaging raising concern for inherited disease, or poor concordance between the presumed syndrome and observed course.[1][4][9] Specialist evaluation is particularly valuable because early differentiation among Parkinson disease, DLB, MSA, PSP, and CBS can be difficult even with contemporary criteria.[1][2]

Discuss research referral selectively when biomarker testing, genetics, or disease-specific trials could alter eligibility, while explaining that alpha-synuclein assays and other biomarkers remain under validation for diagnostic use.[1] Continue symptom-directed treatment and safety interventions irrespective of research participation.
- Use “clinically probable” or “clinical syndrome” language when certainty is limited; avoid labeling CBS as CBD without pathologic confirmation.[4][7]
- Update prognosis and care goals when the patient’s principal source of disability shifts from motor impairment to autonomic, bulbar, cognitive, behavioral, or caregiver-safety complications.[3][7][9]
- Schedule structured longitudinal reassessment because repeated clinical examination is central to identifying treatable complications in time.[2][7]

*Documentation language that preserves clinical utility and diagnostic accuracy.[2][4][6][7]*

| Avoid | Prefer | Reason |
| --- | --- | --- |
| “Parkinson-plus syndrome” as the final diagnosis | “Atypical parkinsonism, phenotype currently most consistent with MSA/PSP/CBS/DLB” | The term encompasses several clinically distinct disorders with different dominant complications and differential diagnoses.[2][4][5] |
| “Corticobasal degeneration” based on asymmetric parkinsonism alone | “Corticobasal syndrome” with documented cortical and motor features | CBD is pathologically defined, whereas CBS is the clinical syndrome used in life.[4][6][7] |
| “Levodopa nonresponse confirms atypical parkinsonism” | “Limited levodopa response is one feature supporting an atypical phenotype; continue serial reassessment” | Clinical differentiation remains difficult, particularly early in disease.[1][2][3] |

## References
1. Revisiting the 2015 MDS diagnostic criteria for Parkinson disease: insights from autopsy-confirmed cases | npj Parkinson's Disease — www.nature.com — https://www.nature.com/articles/s41531-025-01206-6
2. The Differential Diagnosis and Treatment of Atypical Parkinsonism — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC4782269
3. The Spectrum of Cognitive Impairment in Atypical Parkinsonism Syndromes: A Comprehensive Review of Current Understanding and Research — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC11854393
4. Atypical parkinsonian syndromes: a general neurologist’s perspective — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC7646945
5. Diagnostic Approach to Atypical Parkinsonian Syndromes - PMC — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC5567217
6. Progressive supranuclear palsy and corticobasal degeneration: novel clinical concepts and advances in biomarkers — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC9491415
7. Best Practices in the Clinical Management of Progressive Supranuclear Palsy and Corticobasal Syndrome: A Consensus Statement of the CurePSP Centers of Care — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC8284317
8. Available and future treatments for atypical parkinsonism. A ... — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC6488913
9. A Guide for the Differential Diagnosis of Multiple System ... — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC9661336

## Editorial note

Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.